Phase 1 Circadian-Optimized Light Therapy (COLT) supports TIL cell therapy via circadian entrainment.

This single-center, prospective Phase 1 pilot from City of Hope tests whether Circadian-Optimized Light Therapy (COLT)—a timed morning light-exposure program delivered through the Circadian OS iPad app—can be safely added to standard tumor-infiltrating lymphocyte (TIL) therapy for advanced/metastatic melanoma. The intervention aims to stabilize circadian rhythms during a highly disruptive treatment course, using daily 1-hour light sessions starting about 14 days before TIL infusion (day 0) and continuing through ~28 days post-infusion, with optional continuation up to ~90 days. TIL therapy itself is an autologous adoptive cell transfer approach: tumor-reactive T cells are harvested from a patient’s tumor, expanded, and reinfused to drive anti-tumor immune killing. Participants also wear wrist actigraphy and provide serial blood samples to connect sleep/light/circadian measures with immune and inflammatory signals. The key commercial/scientific angle is a low-cost, home-based “digital supportive immunotherapy adjunct” that could improve consistency of immune-cell performance without changing the core cell-therapy product; today’s care for metastatic melanoma is immune checkpoint blockade (anti–PD-1 ± anti–CTLA-4), BRAF/MEK targeted therapy for BRAF V600–mutant disease, and—after progression—options such as lifileucel TIL (Amtagvi, Iovance) in appropriate patients.